မယ်လတိုနင်

မယ်လတိုနင် (အင်္ဂလိပ်: melatonin) သည် တိရစ္ဆာန်၊ အပင်နှင့် အဏုဇီဝကောင် (microbe) တို့တွင် တွေ့ရသော ဟော်မုန်းတမျိုး ဖြစ်သည်။ ^[၁]^[၂]^[၃] တိရစ္ဆာန်တို့တွင် တနေ့တာအတွင်းရှိသော မယ်လတိုနင်ပမာဏသည် အတိုးအလျော့ရှိ၏။ မယ်လတိုနင်သည် ကိုယ်ခန္ဓာ၏ တနေ့တာ ဇီဝဆိုင်ရာလုပ်ဆောင်ချက်တို့ကို ထိန်းကျောင်းသည်။ ^[၄]

မယ်လတိုနင်ကို သွေး-ဦးနှောက်ခြားအကန့် (blood-brain barrier) အပြင်ဘက်ရှိ ပိုင်နီယယ်အရည်အိတ်မှ ထုတ်ပေးကာ သွေးထဲသို့ ပို့သည်။ ^[၅] သွေးထဲရောက်လာသော မယ်လတိုနင်သည် ဓာတ်တိုးဆန့်ကျင်ပစ္စည်းတမျိုး (anti-oxidant) ဖြစ်သည့်အတွက် မယ်လတိုနင်အာရုံရင်း (melatonin receptor) မှ ချက်ချင်း လက်ခံဆောင်ရွက်သည်။ ^[၆]^[၇]

မယ်လတိုနင်ကို ၁၉၅၈ ခုတွင် စတွေ့သည်။ ^[၈] အမေရိကန်အစားအစာနှင့်ဆေးဝါးကြီးကြပ်ရေးက မယ်လတိုနင်ကို ဖြည့်စွက်စာအဖြစ် အသိအမှတ်ပြုထားပြီး ဆရာဝန်ဆေးညွှန်းမလိုဘဲ သဘောရှိ ဝယ်နိုင်သည်။ ^[၉] ကနေဒါတွင်လည်း ထို့အတူပင်။ ^[၁၀] ယူနိုက်တက်ကင်းဒမ်းတွင်မူ ဆရာဝန်ဆေးညွှန်းပါမှ ဝယ်ခွင့်ရသည်။ ^[၁၁] အိပ်ရခက်သော အသက် ၅၄ နှစ်အထက်များကို၎င်း၊ အိပ်မရသော ကလေးနှင့်အရွယ်ရောက်ပြီးသူတို့ကို၎င်း ဆေးအဖြစ်ပေးရန် ဥရောပသမဂ္ဂက ၂၀၀၇ ခု၊ ဩစတေးလျက ၂၀၀၉ ခု အသီးသီး အသိအမှတ်ပြုပေးသည်။ ^[၁၂]^[၁၃]^[၁၄]

မယ်လတိုနင်သောက်၍ အိပ်ပျော်စေသည်ဟူသောသက်သေ ခိုင်ခိုင်မရှိ။ ^[၁၅] ၂၀၁၇ ခု စာရင်းတခုအရ ပုံမှန်ထက် ၆ မိနစ်စော၍ အိပ်ပျော်စေသော်လည်း အိပ်ချိန်ပမာဏကို တိုးစေကြောင်း မတွေ့ရ။ ^[၁၆]

ကိုးကား

↑ "Melatonin Archived 24 September 2015 at the Wayback Machine.". Sleepdex.
↑ Caniato R.; et al. (2003). "Melatonin in plants". Adv. Exp. Med. Biol. Advances in Experimental Medicine and Biology. 527: 593–7. doi:10.1007/978-1-4615-0135-0_68. ISBN 978-0-306-47755-3. PMID 15206778.
↑ Paredes S.D.; et al. (2009). "Phytomelatonin: a review". J. Exp. Bot. 60 (1): 57–69. doi:10.1093/jxb/ern284. PMID 19033551.
↑ Altun A. & Ugur-Altun B. (2007). "Melatonin: therapeutic and clinical utilization". Int. J. Clin. Pract. 61 (5): 835–45. doi:10.1111/j.1742-1241.2006.01191.x. PMID 17298593.
↑ Kaur C. & Ling E.A. (2008). "Antioxidants and neuroprotection in the adult and developing central nervous system". Curr. Med. Chem. 15 (29): 3068–80. doi:10.2174/092986708786848640. PMID 19075654.
↑ Boutin J.A.; et al. (2005). "Molecular tools to study melatonin pathways and actions". Trends Pharmacol. Sci. 26 (8): 412–9. doi:10.1016/j.tips.2005.06.006. PMID 15992934.
↑ Hardeland R (2005). "Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance". Endocrine. 27 (2): 119–30. doi:10.1385/ENDO:27:2:119. PMID 16217125.
↑ Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL (August 2017). "Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders Archived 25 February 2021 at the Wayback Machine." (PDF). Sleep Medicine Reviews. 34: 10–22. doi:10.1016/j.smrv.2016.06.005. PMID 28648359.
↑ "Melatonin: Side Effects, Uses, Dosage (Kids/Adults) Archived 15 December 2018 at the Wayback Machine.". Drugs.com.
↑ "Summary Safety Review – MELATONIN (N-acetyl-5-methoxytryptamine) – Review of the Safety of Melatonin in Children and Adolescents Archived 9 January 2019 at the Wayback Machine.". Government of Canada. Health Canada. 10 December 2015.
↑ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 482–483. ISBN 9780857113382.
↑ "Australian Public Assessment Report for Melatonin Archived 10 January 2019 at the Wayback Machine." (PDF). Australian Government Department of Health and Ageing Therapeutic Goods Administration. January 2011. pp. 2, 4. Monotherapy for the short term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
↑ "Circadin EPAR Archived 20 March 2019 at the Wayback Machine.". European Medicines Agency (EMA). Retrieved 31 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ "Slenyto EPAR Archived 20 March 2019 at the Wayback Machine.". European Medicines Agency (EMA). Retrieved 31 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ Brasure M, MacDonald R, Fuchs E, Olson CM, Carlyle M, Diem S, et al. (2015). "Management of Insomnia Disorder[Internet]". AHRQ Comparative Effectiveness Reviews. 15 (16): EHC027–EF. PMID 26844312. Evidence for benzodiazepine hypnotics, melatonin agonists in the general adult population, and most pharmacologic interventions in older adults was generally insufficient
↑ Matheson E, Hainer BL (July 2017). "Insomnia: Pharmacologic Therapy". American Family Physician. 96 (1): 29–35. PMID 28671376.

[1] "Melatonin Archived 24 September 2015 at the Wayback Machine.". Sleepdex.

[2] Caniato R.; et al. (2003). "Melatonin in plants". Adv. Exp. Med. Biol. Advances in Experimental Medicine and Biology. 527: 593–7. doi:10.1007/978-1-4615-0135-0_68. ISBN 978-0-306-47755-3. PMID 15206778.

[3] Paredes S.D.; et al. (2009). "Phytomelatonin: a review". J. Exp. Bot. 60 (1): 57–69. doi:10.1093/jxb/ern284. PMID 19033551.

[4] Altun A. & Ugur-Altun B. (2007). "Melatonin: therapeutic and clinical utilization". Int. J. Clin. Pract. 61 (5): 835–45. doi:10.1111/j.1742-1241.2006.01191.x. PMID 17298593.

[5] Kaur C. & Ling E.A. (2008). "Antioxidants and neuroprotection in the adult and developing central nervous system". Curr. Med. Chem. 15 (29): 3068–80. doi:10.2174/092986708786848640. PMID 19075654.

[6] Boutin J.A.; et al. (2005). "Molecular tools to study melatonin pathways and actions". Trends Pharmacol. Sci. 26 (8): 412–9. doi:10.1016/j.tips.2005.06.006. PMID 15992934.

[7] Hardeland R (2005). "Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance". Endocrine. 27 (2): 119–30. doi:10.1385/ENDO:27:2:119. PMID 16217125.

[8] Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL (August 2017). "Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders Archived 25 February 2021 at the Wayback Machine." (PDF). Sleep Medicine Reviews. 34: 10–22. doi:10.1016/j.smrv.2016.06.005. PMID 28648359.

[9] "Melatonin: Side Effects, Uses, Dosage (Kids/Adults) Archived 15 December 2018 at the Wayback Machine.". Drugs.com.

[10] "Summary Safety Review – MELATONIN (N-acetyl-5-methoxytryptamine) – Review of the Safety of Melatonin in Children and Adolescents Archived 9 January 2019 at the Wayback Machine.". Government of Canada. Health Canada. 10 December 2015.

[11] British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 482–483. ISBN 9780857113382.

[12] "Australian Public Assessment Report for Melatonin Archived 10 January 2019 at the Wayback Machine." (PDF). Australian Government Department of Health and Ageing Therapeutic Goods Administration. January 2011. pp. 2, 4. Monotherapy for the short term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.

[13] "Circadin EPAR Archived 20 March 2019 at the Wayback Machine.". European Medicines Agency (EMA). Retrieved 31 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[14] "Slenyto EPAR Archived 20 March 2019 at the Wayback Machine.". European Medicines Agency (EMA). Retrieved 31 May 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[15] Brasure M, MacDonald R, Fuchs E, Olson CM, Carlyle M, Diem S, et al. (2015). "Management of Insomnia Disorder[Internet]". AHRQ Comparative Effectiveness Reviews. 15 (16): EHC027–EF. PMID 26844312. Evidence for benzodiazepine hypnotics, melatonin agonists in the general adult population, and most pharmacologic interventions in older adults was generally insufficient

[16] Matheson E, Hainer BL (July 2017). "Insomnia: Pharmacologic Therapy". American Family Physician. 96 (1): 29–35. PMID 28671376.

[၁]

[၂]

[၃]

[၄]

[၅]

[၆]

[၇]

[၈]

[၉]

[၁၀]

[၁၁]

[၁၂]

[၁၃]

[၁၄]

[၁၅]

[၁၆]